Achieved Rapid News Today

/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the presentation of...

RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW 2021 USA - English Two new analyses of Movantik® (naloxegol) data, from almost 900 patients, were presented at Digestive Disease Week 2021 evaluating the onset of action and symptom improvement of Movantik for a broad range of challenging opioid-induced constipation (OIC) symptoms Movantik is an oral peripherally acting mu-opioid receptor antagonist (PAMORA) approved in the U.S. to treat OIC in adult...